Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;6(11):e1903.
doi: 10.1371/journal.pntd.0001903. Epub 2012 Nov 15.

Projecting the long-term impact of school- or community-based mass-treatment interventions for control of Schistosoma infection

Xiaoxia Wang  1 , David Gurarie, Peter L Mungai, Eric M Muchiri, Uriel Kitron, Charles H King
Affiliations

Projecting the long-term impact of school- or community-based mass-treatment interventions for control of Schistosoma infection

Xiaoxia Wang et al. PLoS Negl Trop Dis. 2012.

Abstract

Background: Schistosomiasis remains a significant health burden in many areas of the world. Morbidity control, focused on limiting infection intensity through periodic delivery of anti-schistosomal medicines, is the thrust of current World Health Organization guidelines (2006) for reduction of Schistosoma-related disease. A new appreciation of the lifetime impact of repeated Schistosoma infection has directed attention toward strategies for greater suppression of parasite infection per se, with the goal of transmission interruption. Variations in drug schedules involving increased population coverage and/or treatment frequency are now undergoing field trials. However, their relative effectiveness in long-term infection suppression is presently unknown.

Methodology/principal findings: Our study used available field data to calibrate advanced network models of village-level Schistosoma transmission to project outcomes of six different community- or school age-based programs, as compared to the impact of current 2006 W.H.O. recommended control strategies. We then scored the number of years each of 10 typical villages would remain below 10% infection prevalence (a practicable level associated with minimal prevalence of disease). All strategies that included four annual treatments effectively reduced community prevalence to less than 10%, while programs having yearly gaps ('holidays') failed to reach this objective in half of the communities. Effective post-program suppression of infection prevalence persisted in half of the 10 villages for 7-10 years, whereas in five high-risk villages, program effects on prevalence lasted zero to four years only.

Conclusions/significance: At typical levels of treatment adherence (60 to 70%), current WHO recommendations will likely not achieve effective suppression of Schistosoma prevalence unless implemented for ≥6 years. Following more aggressive 4 year annual intervention, some communities may be able to continue without further intervention for 8-10 years, while in higher-risk communities, annual treatment may prove necessary until eco-social factors fostering transmission are removed. Effective ongoing surveillance and locally targeted annual intervention must then become their mainstays of control.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Schematic view of a networked landscape of Schistosoma transmission.
The diagram indicates the typical overlapping transmission links (gray lines) between human habitation sites (villages V1–V10, black dots) and their respective primary and secondary water contact sites (ponds P1–P5, gray dots) where people become exposed to cercariae from infected host snails. While each village may have its own principal transmission characteristics, this linked meta-population structure can foster more rapid reintroduction of infection in previously treated communities , .
Figure 2
Figure 2. High correlation between pre- and post-treatment prevalence of Schistosoma infection at the local village-level.
Village-level S. haematobium prevalence values for school-age children are plotted for 10 neighboring communities included in the Msambweni Study in coastal Kenya , , . Pretreatment prevalence values from Fall 1983 are indicated on the x-axis, while post-treatment values for 2000 are indicated on the y-axis. During the 1983–2000 interval, the participating communities received school-based targeted drug administration from 1984–1992, after which a funding lapse led to suspension of treatment. The 2000 values thus indicate a robust return of infection prevalence after an 8 year hiatus of control. Pearson correlation (R = 0.83, P<0.001) indicated a strong association between pre- and post-control village-level prevalence values. Corresponding linear regression (y =  1.08x−0.32) indicated that the post control prevalence was, on average, 32 percentage points lower than before control. Nevertheless, all villages relapsed to the moderate or high S. haematobium prevalence categories, with pre-control prevalence an excellent predictor of the level of post-treatment rebound. These and post-treatment data from additional yearly surveys were used to calibrate the SWB model used in this study.
Figure 3
Figure 3. SWB model validation: prediction of 2009 village-level S. haematobium prevalence among school-age children.
Following initial calibration of the programmed SWB model against human and snail S. haematobium prevalence data from 1983–1987 and 2000–2006 , we checked the predictive accuracy of the model against new survey data obtained for two study villages in 2009 after a round of community-wide treatment in 2006. The observed S. haematobium prevalence among school-age children (y-axis) is indicated by black dots for villages 6 and 7. The corresponding gray dots indicate the predictions of the model for these two villages using the model's best-fit parameter values. The box-plots indicate the median, interquartile range, and 95% range of the SWB model predictions in sensitivity analysis, in which model input parameters were allowed to vary at random over a ±20% range. The concordance between observed and predicted values in this and other validation testing provided support for the accuracy of model projections in the present study simulations.
Figure 4
Figure 4. Modeling time-to-success for current WHO treatment strategies, as a function of program adherence.
In this SWB model simulation for the 10 interlinked villages in Figure 1, WHO treatment assignment was made based on current recommendations for high- and moderate-prevalence communities (see Table 2). The bars indicate the number of years required for the overall area school-age population prevalence to drop below 10% (y-axis). This working target is a prevalence level is felt to be associated with minimal risk of advanced schistosomiasis . As shown in the different bars along the x-axis, the time to needed to achieve the <10% global prevalence target varied according to the population participation (adherence) with the implemented treatment program. At 80–90% adherence among children (achieved in many research control programs), it took a minimum of 4 years of treatment (as assigned in year 1, based on starting prevalence) to achieve the <10% target. Where adherence was less good (60–70%, typical of many non-research national programs), control was projected to take appreciably longer (6–8 years on the assigned treatment strategy).
Figure 5
Figure 5. Projected rebound of infection in villages V2 and V6 after community-based treatment for two years.
Graphs indicating the projected 20-year annual infection prevalence experience of two area villages, one of initially high prevalence (village 6, panel A) and one of moderate prevalence (village 2, panel B) during and after a 2-year annual community-wide drug administration campaign followed by a 2-year treatment hiatus (C-C-H-H). The timing of initial treatments is indicated by downward arrows. In the high-prevalence village (panel A), community coverage at 70% adherence among children and 50% adherence among adults reduces school age prevalence below the desired 10% target (gray zone) in two years. However, subsequent implementation of a treatment ‘holiday’ for 2 years results in rapid return of school age prevalence to moderate-level prevalence. At that point, re-implementation of treatment through an annual school age coverage results in continued suppression of prevalence to the <10% level. However, if school age treatment is again suspended after 4 years (dashed line) or 8 years (solid line) of retreatments, childhood prevalence is projected to slip above 10% within 3 years. By contrast, in panel B (lower prevalence Village 2), school age prevalence is adequately suppressed by 2 years of community-based treatment, after which local school age prevalence is expected to remain below 10% (gray zone) for at least 4 years. Here, dashed and solid lines indicate that the duration of school age treatment of village 6, whether for shorter (dashed line) or longer periods (solid line), has only marginal effect on the rebound of infection prevalence that is expected in Village 2.
Figure 6
Figure 6. Likely impact of treatment adherence on long-term suppression of village prevalence using current WHO strategies.
In this simulation, village-level outcomes are projected in terms of the number of post-treatment ‘safe’ years (i.e., years with school age prevalence <10%) that are likely if assigned treatment is ended once an areas achieves a <10% prevalence in all villages. Here, control is achieved using standard WHO treatment assignments, with the differently shaded bars indicating different levels of treatment adherence. (As detailed in Figure 4, such control requires 8 years of treatments when adherence is 60%, 6 years at 70% and 4 years at 80–90% adherence.) Of note, the duration of control varies strongly depending on each village's pre-intervention level of school age infection prevalence. Where adherence is low, the initially high-prevalence villages very quickly rebound to >10% prevalence and associated risk for disease. Where overall coverage is much higher (90%), every village is projected to have at least 3 years of ‘safety’ below 10% school age prevalence. Independent of adherence levels, the 5 villages with the lowest initial prevalence levels were projected to have at least 2 ‘safe’ years after the suspension of program-based treatment.
Figure 7
Figure 7. Projected impact of different SCORE treatment strategies on village level prevalence following 4 years intervention.
Large randomized trials of different schedules of anti-schistosomal drug delivery are now underway, under the auspices of the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) . In this simulation, we examined the likely outcomes of the six different SCORE control strategies on village level prevalence at after 4 years of treatment. School age adherence was set to 70%, and in community-based treatments, adult adherence was assumed to be 50%. C indicates a year of community-based treatment, S indicates a year of school age treatment, and H indicates a ‘holiday’ or non-treatment year. Of note, in the low-prevalence villages, all strategies achieved the goal of reducing village prevalence <10%. Control was obtained in the high prevalence villages only when there were no gaps in treatment, i.e., C-C-C-C, C-C-S-S, or S-S-S-S, with no ‘holidays’ in the schedule.
Figure 8
Figure 8. Likely impact of different SCORE strategies on long-term suppression of village prevalence of Schistosoma infection.
As in Figure 6, we simulated the duration of long term post-control suppression of Schistosoma infection to safer levels below 10%. In this case, overall school age adherence was estimated at 70%, and comparisons were made between the 3 most successful four-year SCORE strategies, and standard implementation of the WHO strategy (which takes 6 years to achieve area control). The more aggressive, every-year SCORE strategies resulted in more prolonged post-treatment suppression of infection prevalence than the WHO protocols (in which some communities get assigned to every-other-year treatment). This was apparent in the six villages with the lowest pre-treatment prevalences (16–44%). In the villages with highest pre-intervention levels of infection (57–69%), all of the strategies were very limited in their ability to effect post-treatment suppression (0 to 2 years only).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. WHO Expert Committee (2004) The World Health Report 2004-Changing History. Geneva: World Health Organization. 96 p.
    1. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Sachs SE, et al. (2006) Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria - A comprehensive pro-poor health policy and strategy for the developing world. Plos Medicine 3: 576–584. - PMC - PubMed
    1. Chitsulo L, Engels D, Montresor A, Savioli L (2000) The global status of schistosomiasis and its control. Acta Trop 77: 41–51. - PMC - PubMed
    1. Jordan P (1985) Schistosomiasis: The St. Lucia Project. Cambridge: Cambridge University Press.
    1. Utzinger J, Zhou XN, Chen MG, Bergquist R (2005) Conquering schistosomiasis in China: the long march. Acta Trop 96: 69–96. - PubMed

Publication types

Substances